PRME — Prime Medicine, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1894562 ·
Last close
$3.58
Market Cap
$649.33M
52W High
$6.65
52W Low
$2.67
ADV30
3,858,611
Next earnings
2026-11-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,154,000 | — | -43,285,000 | -42,109,000 | 249,040,000 | 47,451,000 | 209,231,000 |
| Mar 2026 | 856,000 | — | -50,654,000 | -49,122,000 | 294,730,000 | 64,106,000 | 218,030,000 |
| Dec 2025 | 838,000 | — | -48,608,000 | -46,079,000 | 342,733,000 | 63,032,000 | 221,865,000 |
| Sep 2025 | 1,225,000 | — | -53,973,000 | -50,582,000 | 385,012,000 | 71,396,000 | 223,191,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-156,051,000
Investing CF
$3,629,000
Financing CF
$146,069,000
CapEx
$-797,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.25
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$979,585,000
Inventory
—
Receivables
$120,000
ST Investments
$71,391,000
EBIT TTM
$-196,520,000
Pretax Income TTM
$-187,892,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,073,000
EBITDA
$-189,122,000
Free Cash Flow
$-75,780,000
Enterprise Value
$574,247,488
Total Cash
$95,071,000
Total Debt
$112,478,000
Shares Out
181,376,856
Trailing EPS
$-1.05
Book Value
$0.23
ROE
-373.3%
ROA
-46.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,632,000 | -208,350,000 | -201,142,000 | 342,733,000 | 221,865,000 | 120,868,000 | -162,564,000 |
| Dec 2024 | 2,983,000 | -202,467,000 | -195,882,000 | 297,508,000 | 144,359,000 | 153,149,000 | -122,865,000 |
| Dec 2023 | 0 | -191,292,000 | -198,133,000 | 193,851,000 | 60,780,000 | 133,071,000 | -165,412,000 |
| Dec 2022 | 0 | -116,544,000 | -121,821,000 | 360,314,000 | 44,044,000 | 316,270,000 | -131,827,000 |
TTM Snapshot
Revenues TTM
$4,199,000
NetIncome TTM
$-198,374,000
OpCashFlow TTM
—
Assets (Latest)
$294,730,000
Forward EPS
$-0.88
Max Pain — expiry 2026-10-16
max pain strike: $3.00 · spot: $3.99 · call oi: 6,882 · put oi: 1,360
Expected Move to 2026-10-16:
±$0.55
(13.78%) —
implied range
$3.44 –
$4.54
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DNA | Ginkgo Bioworks Holdings, Inc. | $628.05M | $11.34 | — |
| AURA | Aura Biosciences, Inc. | $674.60M | $6.51 | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $701.60M | $12.70 | — |
| DBVT | DBV Technologies S.A. | $600.20M | $9.55 | — |
| SLDB | Solid Biosciences Inc. | $731.28M | $6.82 | — |
News headlines (Yahoo Finance, 1h cache)
Prime Medicine stock surges on FDA IND clearance
2026-09-24 20:47 · Yahoo
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
2026-09-23 21:49 · Yahoo
Prime Medicine to Participate in Upcoming Investor Conferences
2026-09-03 12:00 · Yahoo
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-06 12:00 · Yahoo
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
2026-07-30 14:00 · Yahoo
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
2026-07-23 20:05 · Yahoo
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics
2026-07-15 08:53 · Yahoo
Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle
2026-07-08 20:09 · Yahoo
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
2026-10-05 12:00 · Yahoo
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
2026-09-29 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.